Recently unearthed emails, letters to regulators and legal strategy documents sent by Allergan, Inc. (NYSE:AGN) executives and their consortium of paid consultants paint a picture of a company engaged in a multiple-prong attack to damage the reputation of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX), sink its stock price and fight a regulatory battle. Allergan’s attempt to manipulate the stock price of Valeant Pharmaceuticals Perhaps most interesting about the 30 some documents reviewed by ValueWalk, many marked “confidential” or “highly confidential,” are what appear to be direct attempts to manipulate the stock price of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX). The…
Emails Show Allergan Asked Goldman To "Take off The Gloves" In Valeant Fight
Mark Melin
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.